The Use of Flow Cytometry in Myelodysplastic Syndromes: A Review

Bento, Laiz Cameirão; Correia, Rodolfo Patussi; Mangueira, Cristóvão Luis Pitangueiras; Barroso, Rodrigo de Souza; Rocha, Fabiana; Bacal, Nydia Strachman; Marti, Luciana Cavalheiro

doi:10.3389/fonc.2017.00270

Cited by 35 publications

(37 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bone marrow multiparametric FC gives complementary information for both MDS diagnosis and prognosis, and it has been introduced as an important co‐criteria for MDS diagnosis . To date, FC in MDS still requires a high level of expertise to analyze and interpret the results, making their daily use in the clinical work‐up of MDS diagnosis difficult .…”

Section: Discussionmentioning

confidence: 99%

“…Bone marrow multiparametric FC gives complementary information for both MDS diagnosis and prognosis, and it has been introduced as an important co-criteria for MDS diagnosis. 1,6,8,[14][15][16][17][18] To date, FC in MDS still requires a high level of expertise to analyze and interpret the results, making their daily use in the clinical work-up of MDS diagnosis difficult. 19,20 Scoring systems can simplify the interpretation of the results and provide useful information for the diagnosis of MDS, with good sensitivity and specificity to discriminate MDS from other cytopenias.…”

Section: Discussionmentioning

confidence: 99%

“…Several FC scoring systems have been published to provide useful information for MDS diagnosis, having good sensitivity and specificity to discriminate MDS from other cytopenias . Currently, many different FC scoring systems are available, containing a wide variability in terms of numbers and combination of markers used, the amount of parameters analyzed, and the weight assigned to each parameter . European Leukemia Net Working Group for FC in MDS (IMDSFlow) recommend the Ogata scoring system for screening purposes .…”

Section: Introductionmentioning

confidence: 99%

“…4,5 Currently, many different FC scoring systems are available, containing a wide variability in terms of numbers and combination of markers used, the amount of parameters analyzed, and the weight assigned to each parameter. 3,5,6 European Leukemia Net Working Group for FC in MDS (IMDSFlow) recommend the Ogata scoring system for screening purposes. 7 This score includes four parameters: percentage of CD34+ myeloid progenitor cells among total nucleated cells; percentage of B-cell progenitors within the CD34+ subset; CD45 expression on myeloid progenitors compared to its expression on lymphocytes; and side scatter (SSC) of granulocytes compared to SSC on lymphocytes.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience

Montauban

Hernandez‐Perez

Velloso

et al. 2019

Int J Lab Hematology

View full text Add to dashboard Cite

Introduction Flow cytometry (FC) is a helpful tool for the diagnosis of myelodysplastic syndrome (MDS). Different FC score systems have been developed. The “Ogata score” is a simple diagnostic score that has been validated having a sensitivity of 69% and a specificity of 92% in low‐risk MDS. We aimed to study the feasibility and the utility of the “Ogata score” for the diagnosis of MDS among Latin America (LA) Laboratories. Methods This is a case and control study conducted in LA institutions members of Grupo Latinoamericano de Mielodisplasia (GLAM). A total of 146 MDS patients and 57 control patients were included. “Ogata score” was calculated. Results The sensitivity of “Ogata score” was 75.6% (95% CI, 66.8‐81.3), specificity was 91.2% (95% CI, 79.7‐96.7), PPV was 95.6% (95% CI, 88.5‐98.3), and NPV was 65.4% (95% CI, 49.1‐71.9). In low/intermediate‐1 IPSS patients group, the sensitivity was 70.1% (95% CI, 60.2‐78.2), specificity was 91.2% (CI‐95%, 79.7‐96.7), PPV was 94.2% (95% CI, 86.4‐97.8), and NPV was 62.1% (95% CI, 53.0‐78.7). In the group of patients “without MDS specific markers” (patients without ring sideroblasts, blast excess, or chromosomal abnormalities), the sensitivity was 66.7% (CI‐95%, 55.8‐76.0), specificity was 91.2% (95% CI, 79.7‐96.7), PPV was 92.3% (95% CI, 82.2‐97.1), and NPV was 63.5% (95% CI, 51.9‐73.5). Conclusions The diagnostic power found in this study was similar to the reported by Della‐Porta et al. Also in LA, the analysis was made in modern equipment with acquisition of at least 100 000 events which permits a good reproducibility of the results.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience

Montauban

Hernandez‐Perez

Velloso

et al. 2019

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

“…Visoki indeks povezan je s nepovoljnom dijagnozom, kao i s većom mogućnosti relapsa nakon alogene transplanta cije. 16,21,23 Pri IPSSu niskog rizika i IPSSu int1 veći broj aberacija povezan je s progresijom bolesti. 10 Ne davna studija Canan Alhan i suradnika pokazala je da bolesnici sa smanjenim SSCom imaju relativno lošiju prognozu.…”

Section: Prognostička Vrijednost Analize Imunofenotipa Protočnom Citounclassified

Flow Cytometry in Myelodysplastic Syndrome. Step Forward.

2019

View full text Add to dashboard Cite

Myelodysplastic syndrome (MDS) represents a heterogeneous group of clonal diseases originating from altered (malignant) hematopoietic stem cells. Clinically, it manifests as cytopenia in peripheral blood, dysplastic changes in one or more cell lines in bone marrow and increased risk of evolution to acute myeloid leukemia (AML). Acquired chromosomal aberrations are detected in 40-50% of MDS patients. According to WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Lion 2008), MDS diagnosis is based on the morphological interpretation of found dysplastic changes, the number of blasts, the presence of ring sideroblasts in bone marrow and the established cytogenetic abnormalities. The progress made in recent years in immunophenotyping of hematopoietic progenitor cells and mature cells of dysplastic bone marrow gives to multiparameter flow cytometric analysis (MFC), although initially included as an optional technique, an opportunity to become a standard part of the integrated MDS diagnosis and prognosis.

show abstract

Myelodysplastic Syndromes

Borate¹

2022

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Primary, secondary, and familial myelodysplastic syndromes (MDS) became a reportable group of malignancies in 2001. Over the past 20 years, there have been tremendous strides in genetic and translational research, which has influenced the pathological diagnosis and classification, risk stratification scoring systems, and genomic characterization of MDS. In certain cases, this has led to more personalized therapy options such as Luspatercept in RARS patients with SF3B1 mutations. In this chapter, we discuss the history behind the various MDS prognostic risk stratification and classifications. We also examine our current understanding of MDS pathophysiology, the complexities with establishing an MDS diagnosis including the evolving diagnostic criteria, and the use of next‐generation sequencing analyses. Then, we outline both the standard of care therapeutic options including hypomethylating agents, and their impact over the past decade, as well as multiple clinical trials and treatment options being investigated for MDS patients. Finally, we discuss what personalized treatments and possible preventative strategies we may expect to see – in the next decade – for MDS development in high‐risk patient populations.

show abstract

The Use of Flow Cytometry in Myelodysplastic Syndromes: A Review

Cited by 35 publications

References 46 publications

Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience

Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience

Flow Cytometry in Myelodysplastic Syndrome. Step Forward.

Myelodysplastic Syndromes

Contact Info

Product

Resources

About